<?xml version="1.0" encoding="UTF-8"?>
<p id="par0130">Along with the implementation of such measures, prioritization of patients by diagnosis and/or type of anticancer treatment should be pursued. Patients with lung cancer diagnosis seem to be more at risk for severe COVID-19, and therefore deserve more careful evaluation (
 <xref rid="bib0225" ref-type="bibr">Passaro et al., 2020</xref>). Data from the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry, which have been presented at the American Association of Medical Oncology (ASCO) 2020 annual meeting, suggest high mortality and low admission to intensive care rates in patients with thoracic malignancies (
 <xref rid="bib0050" ref-type="bibr">Garassino et al., 2020</xref>). Among patients with lung cancer, the overall severity of COVID-19 is high, however there does not seem to be an increased risk of severe disease in patients receiving immunotherapy (
 <xref rid="bib0080" ref-type="bibr">Horn et al., 2020</xref>; 
 <xref rid="bib0170" ref-type="bibr">Luo et al., 2020</xref>).
</p>
